Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual vs triple first-line ART and HIV-1 reservoir dynamics
2019-002733-10Phase 4Completed
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dolutegravir, lamivudine, emtricitabine and tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoint: Change in proviral HIV-1 DNA in CD4+ T cells. Started Jul 2019; status: completed.
02
Drugs
dolutegravirlamivudineemtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2019-002733-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002733-10.